1-benzyl-5-piperazin-1-yl-3,4 dihydro1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
Details for Australian Patent Application No. 2005205016 (hide)
International Classifications
Event Publications
27 July 2006 PCT application entered the National Phase
PCT publication WO2005/067933 Priority application(s): WO2005/067933
15 July 2010 Application Accepted
Published as AU-B-2005205016
11 November 2010 Standard Patent Sealed
2 August 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2005205031-Formulation for treating obesity and associated metabolic syndrome
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser